Literature DB >> 11499560

Relationship between renal function and blood level of chromogranin A.

G Tramonti1, M Ferdeghini, C Annichiarico, M Norpoth, C Donadio, R Bianchi, C Bianchi.   

Abstract

Chromogranin A (CGA) is a low MW (49,000) acidic hydrophilic protein. It is synthesized in the chromaffm granules of the neuroendocrine cells, and has been found circulating in the blood of healthy subjects. The aim of this study was to assess the relationship between serum levels of CGA and renal function. One hundred two renal patients (45 M and 57 F; age 14-76 years, mean 52) participated in the study. Glomerular filtration rate (GFR) was measured by the bladder cumulative method, using 99mTc-DTPA as a tracer. Blood CGA was determined by RIA. Plasma creatinine, beta2microglobulin (beta2m) and tumor associated trypsin inhibitor (TATI) were also determined. The reduction in renal function was associated with an increase in all of the above studied parameters. In patients with advanced renal failure (GFR <20 mL/min) CGA levels increased by 22-fold as compared to the patients with normal renal function (GFR> 100 mL/min). The other studied parameters were also increased but to a lesser degree, e.g., TATI 14-, beta2m 8- and creatinine 5-fold. The results of this study demonstrate that renal handling of the CGA is similar to other low MW proteins, and it accumulates in the blood in renal failure.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11499560     DOI: 10.1081/jdi-100104728

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  15 in total

1.  Assessment of Urine Proteomics in Type 1 Primary Hyperoxaluria.

Authors:  Ellen R Brooks; Bernd Hoppe; Dawn S Milliner; Eduardo Salido; John Rim; Leah M Krevitt; Julie B Olson; Heather E Price; Gulsah Vural; Craig B Langman
Journal:  Am J Nephrol       Date:  2016-05-03       Impact factor: 3.754

2.  Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits.

Authors:  Aldo Spadaro; Antonino Ajello; Carmela Morace; Agata Zirilli; Graziella D'arrigo; Carmelo Luigiano; Francesco Martino; Anna Bene; Domenico Migliorato; Santi Turiano; Oscar Ferraù; Maria-Antonietta Freni
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

3.  Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.

Authors:  Alexander V Fisher; Alexandra G Lopez-Aguiar; Victoria R Rendell; Courtney Pokrzywa; Flavio G Rocha; Zaheer S Kanji; George A Poultsides; Eleftherios A Makris; Mary E Dillhoff; Eliza W Beal; Ryan C Fields; Roheena Z Panni; Kamran Idrees; Paula Marincola Smith; Clifford S Cho; Megan V Beems; Shishir K Maithel; Emily R Winslow; Daniel E Abbott; Sharon M Weber
Journal:  J Gastrointest Surg       Date:  2019-01-18       Impact factor: 3.452

4.  Serum chromogranin A concentration and intradialytic hypotension in chronic haemodialysis patients.

Authors:  Ilona Kurnatowska; Michał Nowicki
Journal:  Int Urol Nephrol       Date:  2006-12-11       Impact factor: 2.370

5.  Chromogranin A polymorphisms are associated with hypertensive renal disease.

Authors:  Rany M Salem; Peter E Cadman; Yuqing Chen; Fangwen Rao; Gen Wen; Bruce A Hamilton; Brinda K Rana; Douglas W Smith; Mats Stridsberg; Harry J Ward; Manjula Mahata; Sushi K Mahata; Donald W Bowden; Pamela J Hicks; Barry I Freedman; Nicholas J Schork; Daniel T O'Connor
Journal:  J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 10.121

6.  Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours.

Authors:  C M Korse; M Muller; B G Taal
Journal:  Br J Cancer       Date:  2011-10-11       Impact factor: 7.640

Review 7.  Tumour markers and kidney function: a systematic review.

Authors:  Giuseppe Coppolino; Davide Bolignano; Laura Rivoli; Giuseppe Mazza; Piera Presta; Giorgio Fuiano
Journal:  Biomed Res Int       Date:  2014-02-06       Impact factor: 3.411

8.  Chromogranin A pathway: from pathogenic molecule to renal disease.

Authors:  Saiful A Mir; Nilima Biswas; Wai Cheung; Ji Wan; Nicholas Webster; Etienne Macedo; Daniel T O'Connor; Sucheta M Vaingankar
Journal:  J Hypertens       Date:  2020-03       Impact factor: 4.776

9.  Prognostic value of circulating chromogranin A levels in acute coronary syndromes.

Authors:  Anna M Jansson; Helge Røsjø; Torbjørn Omland; Thomas Karlsson; Marianne Hartford; Allan Flyvbjerg; Kenneth Caidahl
Journal:  Eur Heart J       Date:  2008-11-21       Impact factor: 29.983

10.  Mast cell activation syndrome as a significant comorbidity in sickle cell disease.

Authors:  Lawrence B Afrin
Journal:  Am J Med Sci       Date:  2014-12       Impact factor: 2.378

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.